- Home
- Psychedelic Drugs Market
Global Psychedelic Drugs Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-271 | No of pages: 238 | Format:
Global psychedelic drugs market is projected to register a CAGR of 13.3% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028
Market Segmentation:
Global Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Belgium, Lithuania, rest of Europe, Saudi Arabia, UAE, Israel and Egypt) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the global psychedelic drugs market are:
Growing acceptance of psychedelic drugs for treating depression, increasing prevalence of depression and mental disorders
Rise in product approvals
Market Players:
The key market players for global psychedelic drugs market are listed below:
Jazz Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)
Pfizer Inc.
Verrian
Avadel
Celon Pharma S.A.
COMPASS
F. Hoffmann-La Roche Ltd
Hikma Pharmaceuticals PLC
NeuroRx, Inc.
PharmaTher Inc.
usonainstitute.org
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 22 1.1 OBJECTIVES OF THE STUDY 22 1.2 MARKET DEFINITION 22 1.3 OVERVIEW OF GLOBAL PSYCHEDELIC DRUGS MARKET 22 1.4 LIMITATIONS 24 1.5 MARKETS COVERED 25 2 MARKET SEGMENTATION 27 2.1 MARKETS COVERED 27 2.2 GEOGRAPHICAL SCOPE 28 2.3 YEARS CONSIDERED FOR THE STUDY 29 2.4 CURRENCY AND PRICING 29 2.5 DBMR TRIPOD DATA VALIDATION MODEL 30 2.6 MULTIVARIATE MODELLING 33 2.7 TYPE OF PSYCHEDELIC DRUGS LIFELINE CURVE 34 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35 2.9 DBMR MARKET POSITION GRID 36 2.10 MARKET APPLICATION COVERAGE GRID 37 2.11 VENDOR SHARE ANALYSIS 38 2.12 SECONDARY SOURCES 39 2.13 ASSUMPTIONS 39 3 EXECUTIVE SUMMARY 40 4 PREMIUM INSIGHT 44 5 EPIDEMIOLOGY 45 6 REGULATORY FRAMEWORK: GLOBAL PSYCHEDELIC DRUGS MARKET 47 6.1 REGULATORY SCENARIO IN INDIA 47 6.2 REGULATORY SCENARIO IN UAE 48 6.3 REGULATORY SCENARIO IN AFRICA 48 6.4 REGULATORY SCENARIO IN THE U.S. 48 6.5 REGULATORY SCENARIO IN BRAZIL 49 6.6 REGULATORY SCENARIO IN THE U.K. 50 7 PIPELINE ANALYSIS 51 8 MARKET OVERVIEW 55 8.1 DRIVERS 57 8.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS FOR TREATING DEPRESSION 57 8.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 58 8.1.3 RISING AWARENESS TOWARDS MENTAL HEALTH 65 8.1.4 ONGOING CLINICAL TRIALS 66 8.1.5 RISE IN PRODUCT APPROVALS 67 8.2 RESTRAINTS 67 8.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 67 8.2.2 HIGH COST OF PSYCHEDELIC DRUGS 71 8.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 73 8.3 OPPORTUNITIES 73 8.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 73 8.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 75 8.3.3 UPCOMING REHABILITATION CENTERS 77 8.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 77 8.4 CHALLENGES 77 8.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 77 8.4.2 RISE IN ALTERNATIVES 79 8.4.3 OTHER TREATMENT OPTIONS 79 9 COVID-19 IMPACT ON GLOBAL PSYCHEDELIC DRUGS MARKET 80 9.1 IMPACT ON PRICE 80 9.2 IMPACT ON DEMAND 80 9.3 IMPACT ON SUPPLY CHAIN 81 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS 81 9.5 CONCLUSION 82 10 GLOBAL PSYCHEDELIC DRUG MARKET, BY SOURCE 83 10.1 OVERVIEW 84 10.2 SYNTHETIC 87 10.3 NATURAL 88 11 GLOBAL PSYCHEDELIC DRUGS MARKET, BY TYPE 89 11.1 OVERVIEW 90 11.2 EMPATHOGENS 93 11.3 DISSOCIATIVES 93 11.4 OTHERS 94 12 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUGS 95 12.1 OVERVIEW 96 12.2 GAMMA-HYDROXYBUTYRIC ACID 99 12.3 KETAMINE 99 12.4 PSILOCYBIN 100 12.5 OTHERS 101 13 GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPPLICATION 102 13.1 OVERVIEW 103 13.2 NARCOLEPSY 106 13.3 TREATMENT RESISTANT DEPRESSION 106 13.4 MAJOR DEPRESSIVE DISORDER 107 13.5 OPIATE ADDICTION 108 13.6 POST-TRAUMATIC STRESS DISORDER 109 13.7 OTHERS 110 14 GLOBAL PSYCHEDELIC DRUG MARKET, BY ROUTE OF ADMINISTRATION 111 14.1 OVERVIEW 112 14.2 ORAL 116 14.3 INHALATION 116 14.4 INJECTABLE 117 15 GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER 118 15.1 OVERVIEW 119 15.2 HOSPITALS 122 15.3 SPECIALTY CLINICS 123 15.4 HOMECARE 123 15.5 OTHERS 124 16 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 126 16.1 OVERVIEW 127 16.2 HOSPITAL PHARMACY 130 16.3 RETAIL PHARMACY 130 16.4 ONLINE PHARMACY 132 17 GLOBAL PSYCHEDELIC DRUGS MARKET, BY REGION 133 17.1 OVERVIEW 134 17.2 NORTH AMERICA 140 17.2.1 U.S. 147 17.2.2 CANADA 149 17.2.3 MEXICO 151 17.3 EUROPE 153 17.3.1 GERMANY 160 17.3.2 U.K. 162 17.3.3 FRANCE 164 17.3.4 ITALY 166 17.3.5 SPAIN 168 17.3.6 RUSSIA 170 17.3.7 POLAND 172 17.3.8 SWITZERLAND 174 17.3.9 NETHERLANDS 176 17.3.10 HUNGARY 178 17.3.11 AUSTRIA 180 17.3.12 NORWAY 182 17.3.13 IRELAND 184 17.3.14 BELGIUM 186 17.3.15 LITHUANIA 188 17.3.16 REST OF EUROPE 190 17.4 MIDDLE EAST & AFRICA 191 17.4.1 SAUDI ARABIA 198 17.4.2 ISRAEL 200 17.4.3 EGYPT 202 17.4.4 UAE 204 18 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 206 18.1 COMPANY SHARE ANALYSIS: GLOBAL 206 18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 207 18.3 COMPANY SHARE ANALYSIS: EUROPE 208 18.4 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 209 19 SWOT 210 20 COMPANY PROFILE 211 20.1 JAZZ PHARMACEUTICALS, INC. 211 20.1.1 COMPANY SNAPSHOT 211 20.1.2 REVENUE ANALYSIS 211 20.1.3 COMPANY SHARE ANALYSIS 212 20.1.4 PRODUCT PORTFOLIO 212 20.1.5 RECENT DEVELOPMENTS 212 20.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 214 20.2.1 COMPANY SNAPSHOT 214 20.2.2 REVENUE ANALYSIS 214 20.2.3 COMPANY SHARE ANALYSIS 215 20.2.4 PRODUCT PORTFOLIO 215 20.2.5 RECENT DEVELOPMENTS 215 20.3 PFIZER INC. 217 20.3.1 REVENUE ANALYSIS 217 20.3.2 COMPANY SHARE ANALYSIS 218 20.3.3 PRODUCT PORTFOLIO 218 20.3.4 RECENT DEVELOPMENTS 218 20.4 VERRIAN 220 20.4.1 COMPANY SNAPSHOT 220 20.4.2 COMPANY SHARE ANALYSIS 220 20.4.3 PRODUCT PORTFOLIO 220 20.4.4 RECENT DEVELOPMENT 220 20.5 AVADEL 222 20.5.1 COMPANY SNAPSHOT 222 20.5.2 REVENUE ANALYSIS 222 20.5.3 COMPANY SHARE ANALYSIS 223 20.5.4 RECENT DEVELOPMENTS 223 20.6 CELON PHARMA S.A. 225 20.6.1 COMPANY SNAPSHOT 225 20.6.2 PIPELINE PORTFOLIO 225 20.6.3 RECENT DEVELOPMENTS 225 20.7 COMPASS 226 20.7.1 COMPANY SNAPSHOT 226 20.7.2 PRODUCT PORTFOLIO 226 20.7.3 RECENT DEVELOPMENTS 226 20.8 F. HOFFMANN-LA ROCHE LTD 227 20.8.1 COMPANY SNAPSHOT 227 20.8.2 REVENUE ANALYSIS 227 20.8.3 PRODUCT PORTFOLIO 228 20.8.4 RECENT DEVELOPMENT 228 20.9 HIKMA PHARMACEUTICALS PLC 229 20.9.1 COMPANY SNAPSHOT 229 20.9.2 REVENUE ANALYSIS 229 20.9.3 PRODUCT PORTFOLIO 229 20.9.4 RECENT DEVELOPMENTS 230 20.10 NEURORX, INC. 231 20.10.1 COMPANY SNAPSHOT 231 20.10.2 PRODUCT PORTFOLIO 231 20.10.3 RECENT DEVELOPMENTS 231 20.11 PHARMATHER INC. 232 20.11.1 COMPANY SNAPSHOT 232 20.11.2 PRODUCT PORTFOLIO 232 20.11.3 RECENT DEVELOPMENTS 232 20.12 USONAINSTITUTE.ORG 234 20.12.1 INSTITUTE SNAPSHOT 234 20.12.2 PIPELINE PORTFOLIO 234 20.12.3 RECENT DEVELOPMENTS 234 21 QUESTIONNAIRE 235 22 RELATED REPORTS 238Segmentation
Short Description Global Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Empathogens, Dissociatives, Others), Drugs (Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others), Application (Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others), Route of Administration (Oral, Inhalation, Injectable), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Belgium, Lithuania, rest of Europe, Saudi Arabia, UAE, Israel and Egypt) Industry Trends and Forecast to 2028 Market Definition: Psychedelic drugs involve various types of chemical substances including LSD and chemical extracted from plants. Psychedelic drugs have the ability to change or enhance the senosory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences. Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD. Market Segmentation The psychedelic drugs market is segmented into seven notable segments which are based on the source, type, drugs, application, route of administration, end user and distribution channel. On the basis of source, the psychedelic drugs market is segmented into synthetic and natural On the basis of type, the psychedelic drugs market is segmented into dissociatives, empathogens and others On the basis of drugs, the psychedelic drugs market is segmented into gamma-hydroxybutyric acid, ketamine, psilocybin and others On the basis of application, the psychedelic drugs market is segmented into narcolepsy, treatment resistant depression, post-traumatic stress disorder, major depressive disorder, opiate addiction and others On the basis of route of administration, the psychedelic drugs market is segmented into oral, inhalation and injectable On the basis of end user, the psychedelic drugs market is segmented into hospitals, specialty clinics, homecare and others On the basis of distribution channel, the psychedelic drugs market is segmented into hospitals pharmacy, retail pharmacy and online pharmacy. Market Players The key market players for global psychedelic drugs market are listed below: Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) Hikma Pharmaceuticals PLC COMPASS Verrian Pfizer Inc. F. Hoffmann-La Roche Ltd Jazz Pharmaceuticals, Inc. PharmaTher Inc. Avadel Celon Pharma S.A. NeuroRx, Inc. usonainstitute.orgMethodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.